BioXcel Therapeutics reports survival results from Phase 2 trial of BXCL701

BioXcel Therapeutics today announced positive overall survival data from its Phase 2 trial of BXCL701, the Company’s investigational oral innate immune activator, in combination with KEYTRUDA in patients with small cell neuroendocrine prostate cancer, SCNC. As of a data cutoff of September 6, 2023, evaluable patients with SCNC showed a median OS of 13.6 months, and a 12-month survival rate of 56.5%. “OS is the most meaningful measure by which the effectiveness of an oncology treatment is evaluated. Though these results are based on a non-randomized cohort of patients, observing a median OS of this duration including patients with long-term survival at 12 months and beyond shows exceptional promise, bearing in mind historic data with checkpoint inhibitor monotherapy in this high-risk subset of prostate cancer,” said Rahul Aggarwal, M.D., Principal Investigator, Associate Director for Clinical Sciences, Helen Diller Family Comprehensive Cancer Center, and Professor of Medicine at the University of California San Francisco. “SCNC represents a major unmet medical need, with the majority of patients unfortunately succumbing to their disease in less than one year following chemotherapy. The results of this trial suggest that BXCL701 has the potential to extend the lives of patients, and I look forward to its continued clinical development.”